1,340 results on '"Falini, Brunangelo"'
Search Results
2. The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML?
3. The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor
4. A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
5. IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML
6. Current status and future perspectives in targeted therapy of NPM1-mutated AML
7. Overlapping features of therapy-related and de novo NPM1-mutated AML
8. The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein
9. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
10. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
11. Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation
12. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
13. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness
14. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors
15. Hairy-Cell Leukemia.
16. Pre‐B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.
17. Mutant NPM1 marginally impacts ribosome footprint in acute myeloid leukemia cells.
18. Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review
19. Myeloid Sarcoma
20. Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
21. Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
22. Rifaximin use favoured micafungin-resistant Candida spp. infections in recipients of allogeneic hematopoietic cell transplantation
23. Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
24. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
25. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia
26. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
27. Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice
28. How I diagnose and treat NPM1-mutated AML
29. Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review
30. Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas
31. Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors.
32. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
33. An unusual form of BRAF‐V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicine
34. Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML
35. Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia
36. Microenvironmental immune cell alterations across the spectrum of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma
37. AML-377 A “Designed” High-Throughput Drug Screening Strategy Identifies Aurora Kinase A Inhibitors as Promising Preclinical Candidates for the Treatment of NPM1-Mutated AML
38. AML-099 Prolonged XPO1 Inhibition Is Essential for Optimal Anti-Leukemic Activity in NPM1-Mutated AML
39. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma
40. Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita
41. GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
42. IDH1-R132 changes vary according to NPM1 and other mutations status in AML
43. ARPIR: automatic RNA-Seq pipelines with interactive report
44. PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML
45. CD47 expression in acute myeloid leukemia varies according to genotype
46. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
47. Myeloid Sarcoma
48. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates
49. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms
50. IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.